Page 42 - RusRPTApr23

However, the spending on drugs by volume was down and the imported niche was hardest hit. Over the week ending March 12, 2023, sales of finished pharmaceuticals in Russia decreased by nearly 37% in physical terms compared to the corresponding week of the previous year. The volume of sold nutritional supplements dropped by nearly 42% y/y, reports Statista.
<a href="https://www.statista.com/statistics/1108147/russia-pharma-sales-volume- growth-by-type/" rel="nofollow"><img src="https://www.statista.com/graphic/1/1108147/russia-pharma-sales-volume- growth-by-type.jpg" alt="Statistic: Weekly y/y sales volume growth of pharmaceuticals in Russia from January 10 to March 12, 2023, by category | Statista" style="width: 100%; height: auto !important; max-width:1000px;-ms-interpolation-mode: bicubic;"/></a><br />Find more statistics at <a href="https://www.statista.com" rel="nofollow">Statista</a>
The US company said it remains committed to supplying these essential medications to Russia and taking necessary measures to ensure uninterrupted access for patients, the source added.
Earlier reports from Kommersant Daily, citing former employees at the company's Russian office, suggested that Eli Lilly was planning to exit the Russian market and transfer its local business to a partner in Central and Eastern Europe, namely Swixx Biopharma.
The agreement represents a significant development in the Russian pharmaceutical market, which has recently undergone regulatory changes. Eli Lilly's continued presence in the market will ensure that Russian patients have access to the medications they need, and it will provide a stable platform for future growth and expansion.
The deal is also a testament to the importance of international collaboration in the pharmaceutical industry. By partnering with Swixx Biopharma, Eli Lilly can take advantage of the distributor's established network in the region, while Swixx Biopharma benefits from access to Eli Lilly's extensive product portfolio.
Overall, the agreement between Eli Lilly and Swixx Biopharma is a positive development for the Russian pharmaceutical market and, most importantly, for Russian patients who depend on life-saving medications to manage their conditions.
2.15 Putin & government’s popularity
Four out of five (80%) Russian trust President Vladimir Putin according to a poll released by state-owned Russian Public Opinion Research Center (VTsIOM) on March 10. However, the percentage of people who approve of the way the president is handling his job fell slightly by 0.2 percentage points to 76.7%.
The poll also showed that 52.1% of those surveyed approved of the Russian
42 RUSSIA Country Report Russia April 2023 www.intellinews.com